New FDA Plausible Mechanism Framework Spurs Development of Personalized In Vivo Prime Editing Platform for Urea Cycle Disorders

Guidance opens doors for rare disease treatments, but academic teams will likely need industry partners to meet rigor required for FDA approval PHILADELPHIA, March 31, 2026 /PRNewswire/ -- Researchers from Children's Hospital of Philadelphia (CHOP) and Penn Medicine, along with...